Sage Therapeutics Explores Strategic Alternatives Amid Biogen Proposal

Sage Therapeutics, Inc. has announced its Board of Directors is exploring strategic alternatives to maximize shareholder value. The options under consideration include potential business combinations, sales, or other strategic transactions. This decision follows Sage’s unanimous rejection of Biogen Inc.’s unsolicited offer to acquire outstanding Sage shares for $7.22 each.

While the review process is underway, Sage emphasizes its commitment to advancing ZURZUVAE as the standard treatment for postpartum depression (PPD). The company has engaged Goldman Sachs as its financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP for legal counsel. Sage has not set a timeline for its strategic review and will provide updates only as necessary, maintaining its focus on delivering value to both patients and shareholders.